A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

  1. Xiangyang Chi
  2. Renhong Yan
  3. Jun Zhang
  4. Guanying Zhang
  5. Yuanyuan Zhang
  6. Meng Hao
  7. Zhe Zhang
  8. Pengfei Fan
  9. Yunzhu Dong
  10. Yilong Yang
  11. Zhengshan Chen
  12. Yingying Guo
  13. Jinlong Zhang
  14. Yaning Li
  15. Xiaohong Song
  16. Yi Chen
  17. Lu Xia
  18. Ling Fu
  19. Lihua Hou
  20. Junjie Xu
  21. Changming Yu
  22. Jianmin Li
  23. Qiang Zhou
  24. Wei Chen

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

A key target for therapeutic antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the spike protein, a trimeric protein complex with each monomer comprising an S1 and an S2 domain that mediate binding to host cells and membrane fusion, respectively. In addition to the receptor binding domain (RBD), S1 has an N-terminal domain (NTD). In searching for neutralizing antibodies, there has been a focus on the RBD. Chi et al. isolated antibodies from 10 convalescent patients and identified an antibody that potently neutralizes the virus but does not bind the RBD. Cryo–electron microscopy revealed the epitope as the NTD. This NTD-targeting antibody may be useful to combine with RBD-targeting antibodies in therapeutic cocktails.

Science , this issue p. 650

Article activity feed

  1. Version published to 10.1126/science.abc6952
  2. ScreenIT

    SciScore for 10.1101/2020.05.08.083964: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: Thank you for sharing your data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.08.083964v1 on bioRxiv